Enterprise Value
71.4B
Cash
8.96B
Avg Qtr Burn
N/A
Short % of Float
1.31%
Insider Ownership
2.54%
Institutional Own.
89.64%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Evkeeza (evinacumab) Details Homozygous familial hypercholesterolemia | Approved Update | |
Kevzara (sarilumab) Details Polymyalgia rheumatica | Approved Quarterly sales | |
EYLEA (aflibercept) Details Diabetic retinopathy | Approved Quarterly sales | |
EYLEA (aflibercept) Details Retinopathy of prematurity | Approved Quarterly sales | |
Dupixent® (dupilumab) (IL-4 IL-13) Details Chronic spontaneous urticaria | PDUFA Approval decision | |
Pozelimab (C5 ANTIBODY) Details Rare diseases, CD55-deficient protein-losing enteropathy | PDUFA Approval decision | |
Aflibercept 8mg Details Diabetic macular edema | PDUFA Approval decision | |
Aflibercept 8mg Details Wet age-related macular degeneration | PDUFA Approval decision | |
Dupixent (DUPILUMAB) Details Skin disease/disorder, Atopic dermatitis | Phase 3 Data readout | |
Dupixent Details Chronic obstructive pulmonary disease | Phase 3 Update | |
Linvoseltamab(BCMAXCD3) Details Blood cancer, Cancer, Multiple myeloma | Phase 2 Update | |
Fianlimab + Libtayo® (cemiplimab) Details Melanoma, Advanced malignancies | Phase 1 Update | |
Dupixent Details Chronic inducible urticaria | Failed Discontinued |